Page 3864 – MPR

Enlon and Enlon-Plus injection discontinued

Baxter Healthcare has decided to discontinue the distribution of Enlon (edrophonium chloride) 10mg/mL injection in the 15mL multi-dose vial and Enlon-Plus (edrophonium chloride and atropine sulfate) injection in the 5mL ampules and 15mL multi-dose vials.

Aloxi gains indication

The FDA has approved Aloxi (palonosetron hydrochloride injection, from Eisai and Helsinn Healthcare) for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

Additional strengths of OxyContin available

Additional strengths of OxyContin available

OxyContin (oxycodone hydrochloride controlled-release tablets, from Purdue Pharma) has been made available in 15mg, 30mg and 60mg dosage strengths in addition to the 10mg, 20mg, 40mg, and 80mg strengths already being marketed.

Tenormin injection discontinued

AstraZeneca has decided to discontinue the manufacturing of Tenormin (atenolol) 0.5mg/mL injection based on business reasons.

Luvox CR approved for OCD and SAD

Luvox CR approved for OCD and SAD

The FDA has approved once-daily Luvox CR (fluvoxamine maleate extended-release capsules, from Jazz) for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD).

FDA issues advisory for Spiriva and Foradil

The FDA has issued a public health advisory highlighting the correct use of Spiriva (tiotropium bromide inhalation powder, from Boehringer Ingelheim) and Foradil (formoterol fumarate inhalation powder, from Schering-Plough) capsules.

Arcalyst approved for CAPS

Regeneron has received FDA approval for Arcalyst (rilonacept injection) for the treatment of cryopyrin-associated periodic syndromes (CAPS) in patients ≥12 years of age.

Abilify gains pediatric indication

The FDA has approved Abilify (aripiprazole, from Otsuka and Bristol-Myers Squibb) for the acute treatment of manic and mixed episodes associated with bipolar I disorder, with or without psychotic features in patients 10-17 years of age.